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Values are presented as the mean ± SD of at least three different exper-
iments. Asterisks represent a p < 0.05 of the effect of carnitine vs control.
These data show that L-carnitine stimulates PDH activity by 50%. However,
the flux of acetyl-CoA and glucose through Kreb's cycle was significantly de-
creased by this compound. These results suggest that L-carnitine enhances
the removal of acetyl-CoA produced from glucose metabolism out of the
mitochondrial matriX, thereby, activating the PDH complex.
L-Carnitine has been shown to protect the myocardium from ischemic in-
jury, and also improves cardiac function in cardiomyopathies associated with
carnitine deficiency and diabetes. However, the exact mechanism whereby
carnitine exerts its effect is not fully understood. The present study was de-
signed to investigate the effect of carnitine on the regulation of glucose uti-
lization in the heart. These studies were performed bl determining the effect
of L-carnitine (5 mM) on the 14C02 release from [1 J C]pyruvate (an index of
pyruvate dehydrogenase complex, PDH), [2-14C]pyruvate (an index of acetyl-
CoA flux through Kreb's cycle). and [6_14C]glucose (an index of the oxidative
utilization of glucose). in rat myocytes.
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In an ongoing ischemic heart disease (IHD) risk factor study, plasma lipid,
Lp(a) and fibrinogen measurements were performed in 2125 men aged 45-
75 years in 1985. The subjects were followed until September 1st 1990. Dur-
ing that period, 116 first IHD events were documented (myocardial infarction,
angina and IHD death). Subjects with IHD were older (59 ± 8 vs 56 ± 7 years;
p < 0.0011. had higher systolic pressure (137 ± 17 vs 130 ± 17 mmHg; p <
0.001). a higher frequency of smoking ~20 cig/d (32 vs 23%; p = 0.027) and
a higher prevalence of diabetes (16 vs 4%; p < 0.001). Total cholesterol (235
± 41 vs 221 ± 39 mg/dL; p < 0.001), LDL-cholesterol (162 ± 37 vs 149 ± 35
mg/dL; p < 0.001), Lp{a) (41.0 ± 45.9 vs 32.7 ± 34.9 mg/dL; p = 0.014) and
fibrinogen (3.89 ± 0.81 vs 3.55 ± 0.75 gil; p < 0.001) levels were higher in
IHD while HDL-cholesterol was lower (37 ± 9 vs 40 ± 10 mg/dL; p ~ 0.005).
Adjusted risk ratios were significantly increased in the third fibrinogen terti Ie
(2.4 ± 0.3; P < 0.001) but not in the second fibrinogen nor in any Lp(a) tertile.
In order to further ascertain the role of fibrinogen and Lp(al. subjects were
assigned to one of four groups according to fibrinogen and Lp(a) levels. The
cutoff point for fibrinogen was the median of the distribution (3.52 gil) and
25 mg/dl for Lp(a).
Group 1: fibrinogen <3.52 gil and Lp(a) <25 mg/dL;
Group 2: fibrinogen <3.52 gil and Lp(a) ~25 mg/dL;
Group 3: fibrinogen ~3.52 gil and Lp(a) <25 mg/dL;
Group 4: fibrinogen ~3.52 gil and Lp(a) ~25 mg/dL.
on polyacrylamide (PAGE; 5 to 16% gradient) and agarose gel electrophore-
sis (0.8% in Tris-HCL buffer). No significant increase was observed in the
basal concentration of MDA between LDL from H and controls (0.8 ± 0.12
and 0.9 ± 0.15 nmoles of MDAlmg of protein, respectively). Instead, afteroxi-
dation MDA was 35.1 ± 4.5* nmoles/mg of protein LDL from H, and 23.5±4.1
in controls (*p < 0.05). PAGE confirmed the purity of LDL. present as an intact
apolipoprotein B100(apo-B 100 ). When oxidized LDL was run on PAGE an ex-
tensive apo-B100 fragmentation, replaced by lower fragments ranging from
97.400 to 205.000 m.w., was only observed in LDL from H but not in controls
in our experimental conditions. MDA content after oxidation of LDL corre-
lated well with the loss of intact apo-B 100. Finally, the relative LDL mobility
on agarose gel was evaluated. This assay allows to detect changes in elec-
tric charge induced by oxidation. Basal LDL from H and controls migrated as
homogeneous bands to 1.2 + 0.2 and 1.1 ± 0.2 cm from the origin. In con-
trast, oxidized LDL from H migrated to 2.1 ± 0.3* cm from the origin while
those of controls migrated to 1.5 ± 0.2 (*p < 0.05). Thus, in FH LDL appear
to be more susceptible to oxidationin vitro; the indices for LDL oxidizability
were all significantly different from those of controls. This phenomenon may
be an important additional mechanism of atherogenesis in homozigous FH.
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These findings were similar in men and women. Multivariate adjustment
for age, gender, body mass index, diabetes, smoking, alcohol intake, and use
of antihypertensive medication did not alter the results.
Conclusion: Decreasing LDL-C levels are associated with decreasing lev-
els of hemostatic risk factors. These findings support the hypothesis that
lipid lowering therapy may reduce clinical events by reducing thrombotic
tendency.
greater degree than it reduces stenosis severity suggest beneficial effects
other than plaque regression. To determine if a favorable lipid profile is asso-
ciated with decreased thrombotic tendency, we determined the relationship
between two hemostatic risk factors, fibrinogen and plasminogen activator
inhibitor (PAI-l), and LDL cholesterol (LDL-C) in 1,878 subjects free of cardio-
vascular disease in the Framingham Offspring Study. The subjects studied
ranged from those with hypobetalipoproteinemia, a condition characterized
by LDL-C :s 70 mg/dl, and a low incidence of thrombosis and coronary heart
disease, to other LDL-C levels grouped by NCEP guidelines.
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Familial hypercholesterolemia (FH) was the first genetic disorder recognized
to cause myocardial infarction. Homozigotes (H) inherit two mutant genes
at the low density lipoprotein (LDL) receptor locus, and as a result of the
increased levels and prolonged residence time of LDL in plasma, there is
a strong tendency toward accumulation of LDL in the arterial wall, causing
early atherogenesis. It has been shown that LDL might undergo oxidation be-
fore it can be taken up by macrophages and it become foam cells. Thus, one
additional explanation for atherogenesis in FH may be the extent to which
LDL is susceptible to oxidation. We selected 8 homozigous FH pts (mean
total-cholesterol 825 ± 70 mg/dl) matched with 8 healthy subjects to inves-
tigate the LDL oxidizability. Skin fibroblast cultures showed that one patient
was receptor negative, while others were receptor-defective. LDL were iso-
lated from serum by ultracentrifugations in KBr. Purified LDL was exposed to
oxygen radicals generated by the xanthine/xanthine oxidase reaction (2 mM
and 100 mU, respectively for 18 hs at 37' C). Malonildihaldehyde (MDAI con-
tent was evaluated by the thiobarbiturate method. LDL analysis was carried
Sterol 27-hydroxylase controls side chain oxidation of bile acids and is
found in vascular endothelial cells. Two metabolites of this oxidation are 27-
hydroxycholesterol (27-0H). which inhibits smooth muscle cell (SMC) pro-
liferation in vivo, and 3tJ-hydroxy-5-cholestenoic acid (C27). We quantified
the inhibitory capacity of both these compounds in vitro using a rabbit aor-
tic SMC preparation. Early passage SMC were grown to confluence, plated
at a density of 5,000 cells/well, and synchronized for 24 hrs. The cells were
then grown in the presence of Dulbecco's modified Eagle's medium with 5%
delipidated fetal calf serum alone (control). in increasing concentrations (1 0,
20,30 ,.,M) of 27-0H and C27 dissolved in 2-hydroxypropyl-tJ-cyciodextrin
(HPBCD). in an equivalent amount of HPBCD alone (control), and in colchicine
(1 mg/dl). Cell proliferation at 24 hrs was measured via formazans formation
from the tetrazolium salt MTS by absorbance at OD 490 nm There was no
significant difference in absorbance between the control and the HPBCD (ab-
sorbance 0.402 ± 0,037 vs 0.400 ± 0.057) or 10 ,.,M concentration 27-0H
(0.383 ± 0.0561 or C27 (0.374 ± 0.022) groups. However, concentrations of
20 and 30 ,.,M of 27-0H produced a significant growth inhibition (0.362 ±
0.030 and 0.350 ± 0.021, P < 0.01) compared to controls, as did C27 at 20
and 30 ,.,M (0.357 ± 0.22 and 0.344 ± 0.28, P < 0.01), while the colchicine
group exhibit the greatest inhibition (0.125 ± 0021). Thus 27-0H and C27
demonstrated a dose response growth inhibition of SMC, and endothelial
sterol 27-hydroxylase may play an important role in modulation of myointi-
mal hyperplasia during the atherosclerotic process.
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